Tetraphase Pharmaceuticals to Present Data at the 22nd Annual MAD-ID Meeting

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced five data presentations at the 22^nd Annual MAD-ID (Making a Difference in Infectious Diseases) Meeting, taking place May 8-11, 2019 in Orlando, Fla. Presentations will include data on XERAVA^TM (eravacycline), a novel, fully-synthetic fluorocycline, approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of complicated intra-abdominal infections.

The details for the data presentations at MAD-ID are as follows:

Poster title: Eravacycline is Effective in High-Risk Complicated Intra-Abdominal Infection Subgroups
Date and time: Thursday, May 9 from 5:00 – 6:30 p.m. ET
Location: Grand Ballroom CDE
Poster number: 75 E

Poster title: Efficacy of Eravacycline in Obese Patients: Pooled Analysis of IGNITE1 and IGNITE4
Date and time: Thursday, May 9 from 5:00 – 6:30 p.m. ET
Location: Grand Ballroom CDE
Poster number: 74 E

Poster title: Effect of Renal Function in IGNITE1 and IGNITE 4: Two Phase 3 Studies to Evaluate the Efficacy and Safety of Eravacycline
Date and time: Thursday, May 9 from 5:00 – 6:30 p.m. ET
Location: Grand Ballroom CDE
Poster number: 73 E

Poster title: Micro Efficacy of Eravacycline Against Enterobacteriaceae and Acinetobacter, Including MDR Isolates: A Pooled Analysis from IGNITE1 and IGNITE4
Date and time: Thursday, May 9 from 5:00 – 6:30 p.m. ET
Location: Grand Ballroom CDE
Poster number: 76 E

Poster title: Multi-Site Evaluation of Eravacycline MIC Test Strip Compared to Broth Microdilution for Enterobacteriaceae, S. aureus and Enterococcus spp.
Date and time: Thursday, May 9 from 5:00 – 6:30 p.m. ET
Location: Grand Ballroom CDE
Poster number: 72 OR

About XERAVA^TM

XERAVA (eravacycline for injection) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. XERAVA was investigated for the treatment of cIAI as part of the Company's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) Phase 3 program. In the first pivotal Phase 3 trial in patients with cIAI, twice-daily intravenous (IV) XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated. In the second Phase 3 clinical trial in patients with cIAI, twice-daily IV XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well-tolerated. In both trials, XERAVA achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates.